Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics Q3 Revenues Soar on Coronavirus Test Sales as Firm Gains Two More CE Marks

NEW YORK — Co-Diagnostics on Tuesday reported third quarter revenues of $21.8 million, compared with $41,434 in the year-ago period. The steep increase was primarily due to sales of its Logix Smart COVID-19 test for SARS-CoV-2.

Separately on Tuesday, the Salt Lake City-based company said that it received CE marks for two additional SARS-CoV-2 tests.

The PCR-based Logix Smart COVID-19 test, which is designed to detect the SARS-CoV-2 RdRp gene, received CE-IVD marking in February and Emergency Use Authorization from the US Food and Drug Administration in April.

Around $1.5 million of Co-Diagnostics' Q3 revenues was related to sales of third-party manufactured equipment and consumables sold to customers to facilitate sales of the SARS-CoV-2 test. The company also said that its Indian joint venture CoSara Diagnostics recorded $3.0 million in third quarter sales, including from SARS-CoV-2 tests.

"Co-Diagnostics continues to see widespread uptake of our COVID-19 test domestically and abroad, and we believe our customer and distributor bases are laying the foundation for a strong future," Co-Diagnostics CEO Dwight Egan said in a statement. "Development projects both completed and ongoing have helped position Co-Diagnostics as a key player in the battle against the coronavirus pandemic, including receipt today of two important CE markings."

The CE marks are for its Logix Smart ABC assay, a combination test for influenza A/B and SARS-CoV-2, and Logix Smart SARS-CoV-2 multi-gene test, which detects both the RdRp and E genes of the virus. Both PCR-based tests use saliva and other respiratory tract samples such as nasal swabs.

For the three-month period ended September 30, Co-Diagnostics post a net profit of $15.7 million, or $.53 per share, versus a loss of $1.7 million, or $.10 per share, a year earlier.

R&D spending in the third quarter almost tripled to $921,889 from $331,027 the year before as the company advanced additional tests through its pipeline, including the newly CE marked tests, and planned SARS-CoV-2 tests that do not require an RNA extraction step.

Third quarter SG&A costs, meantime, more than doubled to $3.0 million from $1.3 million last year.

At the end of September, Co-Diagnostics had cash and cash equivalents totaling $21.2 million.

During early morning trading on the Nasdaq, shares of Co-Diagnostics were down 13 percent to $11.79.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.